|Articles|October 23, 2014

US Healthcare Reform: A Pharm Exec Digest Special

Author(s)The Pharm Exec staff

This month’s special issue of Pharm Exec Global Digest looks at..

This month’s special issue of Pharm Exec Global Digest looks at

Dealing with the “side effects” of Obamacare

The “value” of Rxs under Obamacare

The escalating cost of US oncology care

And more…

Click here to read the issue.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Pharmaceutical Executive Daily: Lilly and Novo Nordisk Bring GLP-1s to TrumpRX

ByNicholas Jacobus

November 7th 2025

Image Credit: Adobe Stock Images/Tada Images. The latest selections for the CNPV include therapies for obesity, cancer, sickle cell disease, and drug-resistant tuberculosis.

FDA Continues to Expand National Priority Voucher Program

ByDavy James

November 7th 2025

FDA Approves Johnson and Johnson’s Darzalex Faspro for Adults with High-Risk Smoldering Multiple Myeloma

ByNicholas Jacobus

November 7th 2025

Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?

ByThani Jambulingam, PhD

November 7th 2025

Deb Nevins is the Chief Marketing & Strategy Officer at POCN Group. POCN Group, an IQVIA business, is the life-sciences engagement division of POCN.

In Obesity Care, NPs and PAs Are the Influencers Marketers Can’t Ignore

ByDeb Nevins

November 7th 2025